The Update: Three New Fronts Opened

Our previous coverage flagged the FDA's Breakthrough designation for a KRAS-targeting drug and early-stage senolytic research. Now there are three distinct new findings — from UCLA, Indiana University, and reporting by the Washington Post on the KRAS pancreatic cancer story — each pointing to fresh vulnerabilities in cancers that have resisted treatment for decades.

UCLA Cracks Small Cell Neuroendocrine Cancers

Small cell neuroendocrine cancers — which can appear in the lung, prostate, and ovary — grow fast, spread early, and have had essentially the same survival odds for 50 years.

According to UCLA Health, researchers at the UCLA Health Jonsson Comprehensive Cancer Center published a new study in the Proceedings of the National Academy of Sciences on March 20, 2026. They found that when these cancers lose a protective gene called RB — which normally acts as a brake on cell growth — they become dangerously dependent on a different protein called E2F3 to survive.

Block E2F3, and the cancer cells die. Scientists call this "synthetic lethality."

"Discovering a vulnerability like this opens the door to thinking about entirely new treatment strategies," said Dr. Owen N. Witte, the study's senior author and Presidential Chair in Developmental Immunology at UCLA. Witte has been working on these tumor models for over a decade. He noted the survival statistics when he first saw these cancers as a medical student more than 50 years ago remain essentially unchanged today.

The team built new lab models by genetically altering normal human prostate cells — introducing five cancer-driving mutations including loss of RB and TP53 — growing them as organoids and then forming tumors in mice. That's the kind of painstaking model-building that makes eventual drug development possible.

This is early-stage research. No human trials yet. But it's the first credible biological roadmap for cancers that have been flying blind for half a century.

Indiana University Targets the Root of Blood Cancer Relapse

Acute myeloid leukemia — AML — kills because it comes back. Chemotherapy wipes out most cancer cells, but a small population of leukemia stem cells hides, survives, and rebuilds the disease. The five-year survival rate sits at just 33 percent, according to national cancer statistics reported by Knowridge Science Report.

Around 22,000 new AML cases were reported in the United States in 2025 alone.

A new study co-led by scientists at the Indiana University School of Medicine, published in the journal Leukemia, examined those stubborn stem cells — taken from AML patients both at initial diagnosis and after relapse. The finding: these cells are heavily dependent on an inflammation pathway called interleukin-1 (IL-1) signaling.

IL-1 is a molecule the immune system uses to send danger signals. AML cells appear to be hijacking it as a survival mechanism. The researchers found IL-1 activity was unusually high in leukemia stem cells at both stages — at diagnosis and after relapse. This persistence across disease stages distinguishes it from features of early disease alone.

IL-1 inhibitors already exist as FDA-approved drugs for inflammatory conditions. That gives researchers a potential head start — testing existing compounds against a newly identified cancer vulnerability rather than building a molecule from scratch.

This represents a specific, testable target in cells that have previously been near-untouchable, though clinical application remains distant.

The KRAS Pancreatic Cancer Story Gets Deeper Context

The Washington Post's Carolyn Y. Johnson reported on the long arc of the KRAS story in pancreatic cancer — a disease where only 13 percent of patients are alive five years after diagnosis. Scientists first identified the mutated KRAS protein as a key driver of pancreatic cancer in the early 1980s. It drives nearly every single case.

For decades, KRAS was considered "undruggable." The protein's structure gave chemists no obvious place to attach a molecule and shut it down.

Our prior coverage noted the FDA's Breakthrough Therapy designation for a new KRAS-targeting drug. The Washington Post piece provides the scientific backstory for why that designation carries weight: it represents the end of a 40-year search for a handle on the most common driver of one of the most lethal cancers in existence.

What Mainstream Coverage Is Missing

Most outlets are treating each of these stories as isolated feel-good science pieces. The broader pattern is that multiple independent research teams — using completely different methodologies, targeting completely different cancers — are simultaneously finding exploitable weaknesses in tumors that have been treatment-resistant for generations.

One overlooked angle: the lag time between "we found a vulnerability" and "patients can access a drug" is measured in years, sometimes decades. The UCLA and Indiana findings are animal- and lab-model stage. Readers deserve that context alongside the hope.

No major outlet is drawing the line between the IL-1 pathway finding and the existing IL-1 inhibitor drugs already on the market — a potentially important shortcut that deserves prominent coverage, not a footnote.

What This Means for Real People

If you or someone you know has AML, small cell lung cancer, small cell prostate cancer, or pancreatic cancer, these findings don't help today. Don't let headlines imply otherwise.

What they show is that scientists are finally mapping terrain that was previously uncharted. The KRAS work demonstrates that "undruggable" is not permanent. The UCLA and Indiana findings show that cancer's survival tricks can become its fatal weaknesses.

The pace of research in oncology right now is accelerating. Whether the funding keeps pace with the science — that's the question few outlets are examining.